Drug intelligence / Profile preview

Quyu Yangmai Fang

Development stage: Preclinical
Administration: Oral

Overview

Quyu Yangmai Fang (祛瘀养脉方) is a Traditional Chinese Medicine (TCM) formula designed to address carotid atherosclerosis accompanied by plaque formation, particularly in patients presenting with kidney deficiency, blood stasis, and phlegm-damp obstruction. The formula aims to tonify kidney essence, resolve blood stasis, unblock collaterals, soften blood vessels, and eliminate atherosclerotic plaques. It is composed of a specific blend of traditional Chinese herbs, including Epimedium (淫羊藿), Eupolyphaga (土鳖虫), Ganoderma lucidum (灵芝), Salvia miltiorrhiza (丹参), Curcuma longa (姜黄), Crataegus pinnatifida (山楂), Taraxacum (蒲公英), and Morus alba (桑叶). The drug is administered orally as a decoction.

Other names: 祛瘀养脉方Ruanmai Huaban Tang软脉化斑汤

Beyond the preview

Go deeper on Quyu Yangmai Fang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quyu Yangmai Fang.

Explore the full profile